ARTES Biotechnology
ARTES Biotechnology is a global and reliable technology provider for the production of recombinant proteins, specializing in microbial cell line and process development for vaccines, biopharmaceuticals, biosimilars, and enzymes. They offer transfer processes for enzymes, vaccines, and biosimilars, and have a broad portfolio of proprietary technologies including VLP vaccine development. The company operates worldwide from its facilities in Langenfeld, Germany, and has a history of over 20 years of successful partnerships with human and animal health companies, enzyme manufacturers, and the cosmetic, diagnostic, and nutrition industries.
Industries
Nr. of Employees
small (1-50)
ARTES Biotechnology
Elisabeth-Selbert-Straße 9, 40764 Langenfeld, Germany
Patents
Method for production of a heterologous protein using yeast-type host cells
US-7858343-B2
View Details
Method for production of a heterologous protein using yeast-type host cells
US-7858343-B2
View DetailsProducts
Research reagents: recombinant antigens, enzymes and functional proteins
Catalog of recombinant research reagents produced in microbial expression systems for use in academic and industrial laboratories.
Recombinant Human Serum Albumin (rHSA) — research grade
Small‑batch recombinant human serum albumin produced in yeast for laboratories and industry needing high‑quality recombinant albumin for research applications.
Research reagents: recombinant antigens, enzymes and functional proteins
Catalog of recombinant research reagents produced in microbial expression systems for use in academic and industrial laboratories.
Recombinant Human Serum Albumin (rHSA) — research grade
Small‑batch recombinant human serum albumin produced in yeast for laboratories and industry needing high‑quality recombinant albumin for research applications.
Services
Contract development services for microbial production cell lines and process development for recombinant proteins and vaccines, including feasibility studies, expression optimization, cell bank generation, and preliminary fermentation.
Upstream and downstream process development focusing on reproducibility, cost reduction and transferability to cGMP manufacturing; includes in‑process controls and assay development.
Manufacturing services for test and preclinical material at non‑GMP and cGMP standards, including upscaling, quality control, method transfer and project management.
Design and development of VLP‑based vaccine candidates and antigen display strategies, including expression in yeast hosts, VLP purification process development and immunogenicity testing in animal models.
Out‑licensing and transfer of processes, cell lines and documentation with training and on‑site support; negotiation of commercial licensing terms and technical implementation support.
Contract development services for microbial production cell lines and process development for recombinant proteins and vaccines, including feasibility studies, expression optimization, cell bank generation, and preliminary fermentation.
Upstream and downstream process development focusing on reproducibility, cost reduction and transferability to cGMP manufacturing; includes in‑process controls and assay development.
Manufacturing services for test and preclinical material at non‑GMP and cGMP standards, including upscaling, quality control, method transfer and project management.
Design and development of VLP‑based vaccine candidates and antigen display strategies, including expression in yeast hosts, VLP purification process development and immunogenicity testing in animal models.
Out‑licensing and transfer of processes, cell lines and documentation with training and on‑site support; negotiation of commercial licensing terms and technical implementation support.
Expertise Areas
- Microbial cell line development
- Fermentation and downstream bioprocess development
- Virus‑like particle (VLP) vaccine development
- Technology transfer and licensing of bioprocesses
Key Technologies
- Hansenula polymorpha yeast expression
- Pichia and Saccharomyces yeast expression
- E. coli expression systems
- Virus‑like particle (VLP) platforms for antigen display
News & Updates
ARTES Biotechnology and Basic Pharma announced a strategic collaboration for the development and production of non-GMP recombinant proteins, including Human Serum Albumin derived from Hansenula polymorpha.
ARTES Biotechnology and Burnet Institute published data on the production and immunogenicity of malaria transmission-blocking vaccine candidates using virus-like particles (VLPs).
ARTES Biotechnology and Burnet Institute announced collaboration to develop a novel hepatitis C virus (HCV) vaccine using VLP technology and proprietary platforms.
ARTES Biotechnology and Basic Pharma announced a strategic collaboration for the development and production of non-GMP recombinant proteins, including Human Serum Albumin derived from Hansenula polymorpha.
ARTES Biotechnology and Burnet Institute published data on the production and immunogenicity of malaria transmission-blocking vaccine candidates using virus-like particles (VLPs).
ARTES Biotechnology and Burnet Institute announced collaboration to develop a novel hepatitis C virus (HCV) vaccine using VLP technology and proprietary platforms.